Medicare Part D drugs starting with K
35 drugs start with K; 13 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Kisqali in 2024: $775 million, what plans and patients paid at the pharmacy before rebates.
Which drugs start with K?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Kaitlib Fe (ethinyl estradiol / norethindrone) | 45.9% | Tier 2 | $28 thousand |
| Kaletra (lopinavir / ritonavir) | 100% | Tier 4 | $295 thousand |
| Kalydeco (ivacaftor) | 76.4% | Tier 5 | $29 million |
| Kariva (desogestrel / ethinyl estradiol) | 96.4% | Tier 2 | $51 thousand |
| Katerzia (amlodipine) | 0.4% | Tier 4 | $2 million |
| Kelnor (ethinyl estradiol / ethynodiol diacetate) | 97.4% | Tier 2 | $102 thousand |
| Keppra (levetiracetam) | under 0.1% | Tier 1 | $97 million |
| Kerendia (finerenone) | 100% | Tier 3 | $396 million |
| Kesimpta (ofatumumab) | 77.8% | Tier 5 | $583 million |
| Ketoconazole | 100% | Tier 2 | $82 million |
| Ketodan (ketoconazole) | 13.5% | Tier 4 | $28 thousand |
| Ketoprofen | 5.8% | Tier 4 | $2 million |
| Ketorolac tromethamine | 100% | Tier 2 | $35 million |
| Keveyis (dichlorphenamide) | 0.1% | Tier 5 | $24 million |
| Kevzara (sarilumab) | 2.3% | Tier 5 | $172 million |
| Khindivi (hydrocortisone) | 2.3% | Tier 5 | no 2024 match |
| Kineret (anakinra) | 68.2% | Tier 5 | $32 million |
| Kinrix (DTaP-IPV vaccine) | 100% | Tier 1 | $10 thousand |
| Kionex (sodium polystyrene sulfonate) | 78.4% | Tier 3 | $435 thousand |
| Kisqali (ribociclib) | 100% | Tier 5 | $775 million |
| Kitabis (tobramycin) | 2% | Tier 5 | no 2024 match |
| Klaron (sulfacetamide sodium) | under 0.1% | Tier 1 | no 2024 match |
| Klisyri (tirbanibulin) | 9.9% | Tier 5 | $3 million |
| Klor-Con (potassium chloride) | 99.4% | Tier 2 | $13 million |
| Kloxxado (naloxone hydrochloride) | 100% | Tier 3 | $364 thousand |
| Korlym (mifepristone) | 3% | Tier 5 | $342 million |
| Koselugo (selumetinib) | 100% | Tier 5 | $22 million |
| Kourzeq (triamcinolone acetonide) | 58.1% | Tier 3 | no 2024 match |
| Krazati (adagrasib) | 100% | Tier 5 | $70 million |
| Krintafel (tafenoquine) | 4.1% | Tier 4 | no 2024 match |
| Kristalose (lactulose) | 13.3% | Tier 4 | $4 million |
| Kurvelo (ethinyl estradiol / levonorgestrel) | 95.8% | Tier 2 | $104 thousand |
| Kuvan (sapropterin dihydrochloride) | under 0.1% | Tier 1 | $3 million |
| Kyleena (levonorgestrel) | 3.7% | Tier 4 | $43 thousand |
| Kymbee (deflazacort) | 13.9% | Tier 5 | no 2024 match |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans